| Treatment guidelines for depression in the Asia Pacific region: a review of current developments. | |
| | |
MedLine Citation:
|
PMID: 15715828 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: This paper examines the development of treatment guidelines, medication algorithms and clinical pathway guides for depression in countries participating in the SEBoD Initiative. METHODS: A systematic review of the extent of development of treatment guidelines, medication algorithms or clinical pathway guides for depression in participating countries. RESULTS: Most countries in the Asia Pacific region have commenced the development of treatment guidelines, medication algorithms or clinical pathway guides. The promoters of such efforts have included a range of professional and government bodies. Most efforts have borrowed heavily on existing international guidelines. There is a significant emphasis on medication practices in most countries, with less emphasis on the role of psychological or other non-pharmacological approaches. There has been insufficient emphasis on integrating local classification, assessment and cultural practices into the provision of high quality care. Important additional measures, including practice surveys and consensus judgements, have been undertaken in some countries. CONCLUSIONS: The development of a genuine quality improvement movement for depression treatments is in its infancy in the Asia Pacific region. However, there is now the capacity to bring together such efforts at a regional level and, in doing so, promote standards for best care, more community and professional involvement and the uptake of a wider variety of treatment approaches. |
| | |
Authors:
|
Ian Hickie |
Related Documents
:
|
20957728 - A structural equation model relating work stress, coping resource, and quality of life ... 10127298 - Application of quality improvement techniques to the reduction of turnaround time for "... 17019208 - Indicators of anesthesia safety and quality. 12466168 - The minimum occlusion trial for the treatment of amblyopia. 7203778 - Control of confounding in the assessment of medical technology. 10111528 - What are our patients taking? do simple instructions help us to find out? |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists Volume: 12 Suppl ISSN: 1039-8562 ISO Abbreviation: Australas Psychiatry Publication Date: 2004 |
Date Detail:
|
Created Date: 2005-02-17 Completed Date: 2005-03-31 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9613603 Medline TA: Australas Psychiatry Country: Australia |
Other Details:
|
Languages: eng Pagination: S33-7 Citation Subset: IM |
Affiliation:
|
Brain & Mind Research Institute, PO Box M160, Camperdown, NSW 1450, Australia. ianh@med.usyd.edu.au |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antidepressive Agents
/
therapeutic use Asia, Southeastern Combined Modality Therapy / trends Critical Pathways / trends* Depressive Disorder / diagnosis, therapy* Forecasting Humans Practice Guidelines as Topic* Psychotherapy / trends Quality Assurance, Health Care / trends |
| Chemical | |
Reg. No./Substance:
|
0/Antidepressive Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A preliminary survey of undergraduate education on depression in medical schools in the Asia Pacific...
Next Document: Can we reduce the burden of depression? The Australian experience with beyondblue: the national depr...